Why Your Krankenkasse Doesn't Cover the Tests That Matter Most

Switzerland operates one of the most sophisticated healthcare systems in the world. It is also, by design, a system that does not routinely fund comprehensive preventative blood screening for healthy adults.

This is not a flaw. It is a deliberate structural choice — and understanding it is the first step to navigating it intelligently.

How the KVG actually works

Switzerland's compulsory health insurance, governed by the Krankenversicherungsgesetz (KVG), reimburses medical services that are "effective, appropriate, and economical" for diagnosed or suspected conditions. Preventative blood testing for asymptomatic, healthy individuals falls outside this framework for most markers beyond a narrow set.

The exception is the periodic health examination (Vorsorgeuntersuchung), which GPs can perform once every three years. This covers blood pressure, BMI, a basic lipid panel, and fasting glucose — roughly the 12–20 markers described above.

The actuarial logic — and its limits

From an insurer's perspective, covering comprehensive preventative screening for the entire Swiss adult population would cost CHF 300–500 million annually. The health economics literature is divided on whether this produces net savings within a standard 5-year coverage window, particularly when accounting for downstream costs of incidental findings.

From an individual's perspective, this calculation is irrelevant. If you are one of the 20% of Swiss adults with an undetected Lp(a) elevation, or one of the 40% with subclinical insulin resistance, or one of the 15% with early thyroid autoimmunity — population-level economics are not your concern. Your biology is.

What out-of-pocket screening actually costs

Aeonix's Prime Health panel — 35 clinically validated biomarkers with physician review — is CHF 895 as a one-time test. The subscription price is CHF 595 per year. For context: the average Swiss household spends CHF 340 per month on KVG premiums (CHF 4,080/year) for basic insurance that covers almost none of what Aeonix measures.

The question is not whether you can afford comprehensive screening. It is whether you can afford not to have it.